Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topics
- Shortages and supply disruptions (19)
- Safety monitoring and information (12)
- Manufacturing (7)
- Compliance and enforcement (6)
- Labelling and packaging (4)
- Import and export (3)
- Scheduling (national classification system) (3)
- Committees and advisory bodies (2)
- Legislation (2)
- Advertising (1)
- Clinical trials (1)
- Fees and payments (1)
- Medicinal cannabis hub (1)
Collection content
110 result(s) found, displaying 1 to 10
-
PageOVERALL SUPPLY IS STABLE. THE SSSI LAPSED ON 31 MARCH 2026.
-
FormsForms for notifying the TGA of a change in sponsorship.
-
PagePharmaceutical companies Novo Nordisk and Eli Lilly are gradually discontinuing some of their earlier generation insulin products. Our webpage lists affected products and includes alternative options.
-
PageInformation about the shortage and the Serious Scarcity Substitution Instrument
-
GuidanceThis guidance is to assist entities and individuals planning to export medicines (including prescription, over-the-counter (OTC) and complementary medicines) either for commercial supply, or for non-commercial purposes (for example, for a family member or friend).
-
PageInformation about the shortage, Serious Scarcity Substitution Instrument and overseas-registered alternative
-
PageKey information and updates about the shortage of Creon (pancreatic extract) capsules.
-
PageFind out about the shortage of Pegasys (peginterferon alfa-2a) injection.
-
PageInformation for sponsors and applicants preparing applications and requests involving steps in the manufacture of medicines regulated as prescription medicines.
-
Medicine shortage alertsWe have extended the SSSI in response to the ongoing shortage